Commentary|Videos|August 12, 2024
Small Clones, Outsized Consequences: The Many Faces of Clonal Hematopoiesis
Danielle E. Hammond, MD, FRCP(C), of The University of Texas MD Anderson Cancer Center, discusses the many faces of clonal hematopoiesis.
The PCR-based OncoMate MSI Dx Analysis System can now identify patients with MSI-H solid tumors who may be eligible for pembrolizumab.
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.